계명대학교 의학도서관 Repository

Use of adjuvant chemotherapy in hormone receptor‑positive breast cancer patients with or without the 21‑gene expression assay

Metadata Downloads
Author(s)
Soo Jin ParkMoo Hyun LeeSun‑Young KongMi Kyung SongJungnam JooYoungmee KwonEun‑Gyeong LeeJai Hong HanSung Hoon SimSo‑Youn JungSeeyoun LeeKeun Seok LeeIn Hae ParkEun Sook Lee
Keimyung Author(s)
Lee, Moo Hyun
Department
Dept. of Surgery (외과학)
Journal Title
Breast Cancer Res Treat.
Issued Date
2018
Volume
170
Issue
1
Keyword
Breast cancer21-gene expression assayAdjuvant chemotherapyMolecular markerProgesterone receptorKi-67
Abstract
Purpose
We assessed the use of chemotherapy in breast cancer patients to investigate the factors that changed trends in chemotherapy following the adoption of the 21-gene expression assay in tumor genomic profiling.

Methods
Our study used 2033 patients from the National Cancer Center in Korea diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (tumor size of 0.5 cm or larger and 0–3 node metastases) from 2010 to 2015. We analyzed use of the 21-gene expression assay, changes in frequency of adjuvant chemotherapy use, and clinicopathological factors related to adjuvant chemotherapy to assess the impact of the 21-gene expression assay.

Results
Adjuvant chemotherapy use declined from 33.33% (2011) to 13.59% (2015) [relative risk (RR), 0.71; 95% CI 0.56–0.89; ptrend = 0.004] in patients with 21-gene expression assay data. Among patients without assay data, adjuvant chemotherapy use decreased from 76.79 to 40.17% between 2010 and 2015 (RR 0.87; 95% CI 0.84–0.91; ptrend < 0.001), especially for patients with node-negative/micrometastasis (RR 0.85; 95% CI 0.81–0.89; ptrend < 0.001). The frequency of adjuvant chemotherapy was significantly decreased after introduction of the 21-gene expression assay (p < 0.001). Tumor size (p < 0.001), progesterone receptor (PgR) status (p = 0.001), and proliferation index (Ki-67) levels (p < 0.001) were important factors for chemotherapy decision-making in node-negative/micrometastasis patients who did not undergo the assay.

Conclusions
For HR-positive, HER2-negative breast cancer patients with 0–1 node metastases, chemotherapy use declined significantly after the adoption of the 21-gene assay. PgR status and Ki-67 were useful for chemotherapy decision-making in cases without the 21-gene assay.
Keimyung Author(s)(Kor)
이무현
Publisher
School of Medicine (의과대학)
Citation
Soo Jin Park et al. (2018). Use of adjuvant chemotherapy in hormone receptor‑positive breast cancer patients with or without the 21‑gene expression assay. Breast Cancer Res Treat., 170(1), 69–76. doi: 10.1007/s10549-018-4740-z
Type
Article
ISSN
1573-7217
Source
https://link.springer.com/article/10.1007%2Fs10549-018-4740-z
DOI
10.1007/s10549-018-4740-z
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41695
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Surgery (외과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.